請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18042
標題: | 建立斑馬魚異體移植模式探討陽離子抗菌蛋白TP4治療三陰性乳癌的功效 Generation of a zebrafish xenograft model of triple-negative breast cancer for evaluating the therapeutic efficacy of Tilapia piscidin 4 (TP4) |
作者: | Yi-Chun Chen 陳儀君 |
指導教授: | 陳志毅(Jyh-Yih Chen) |
關鍵字: | TP4,三陰性乳癌,FOSB,異體移植斑馬魚, TP4,triple negative breast cancer (TNBC),FOSB,xenograft zebrafish, |
出版年 : | 2015 |
學位: | 碩士 |
摘要: | 傳統外科手術、荷爾蒙及標靶藥物均難以有效治療三陰性 (ER/PR/HER2) 的轉移性惡性乳癌。三陰性乳癌細胞雖然對於傳統化療藥物有良好的反應,但是化療藥物對於正常細胞與癌細胞之間並無區別性,反而會造成癌細胞產生抗藥性並且具有極大副作用。因此尋找化療藥物的分子標的將有助於開發對於三陰性乳癌細胞具有專一性毒性之藥物。陽離子抗菌胜肽對於乳癌細胞與正常細胞之間具有選擇性的毒殺作用。Tilapia piscidin 4 (TP4) 為Nile tilapia(Oreochromis niloticus)所分泌的一種陽離子抗菌胜肽。人工合成之TP4能有效抑制革蘭氏陽性及陰性菌的生長,但對於是否具有毒殺癌細胞之能力仍未進一步評估。本研究使用包括三陰性惡性乳癌細胞與其它具有不同分子表達趨勢之惡性乳癌細胞來評估TP4抗腫瘤能力;並進一步利用基因體學分析TP4可能在乳癌細胞中誘導之潛力治療因子。此外,我們利用斑馬魚異體移植模式進一步探討TP4的治療潛力。
經由細胞存活分析實驗顯示,人工合成之TP4能夠選擇性的毒殺惡性乳癌細胞株 (MDA-MB-231/MDA-MB-453/MCF-7) 而對於正常細胞 (M10/HDF) 的毒性相對輕微。利用基因微陣列分析 (Microarray analysis) 發現,TP4可以調控MDA-MB-231細胞內FOS家族轉錄因子表現量。使用細胞轉染實驗證實大量表達FOS家族轉錄因子之一的FOS可以引導惡性乳癌細胞死亡。此外,我們發現MDA-MB-231異體移植對斑馬魚造成顯著死亡;而在不影響斑馬魚胚胎發育,且不傷害魚體表皮及較不影響生存的安全劑量下,我們發現TP4可以延長MDA-MB-231異體移植斑馬魚之壽命。 本論文證實TP4對於三陰性乳癌細胞具選擇性毒殺能力並具有治療三陰性乳癌之潛力。此外FOSB亦可作為有效治療藥物的預後因子。 Among the breast cancer subtypes, triple negative breast cancer (TNBC) (ER/PR/HER2) is particularly challenging and difficult-to-treat. Combinations of surgery, hormone, irradiation, and targeted therapies are not usually effective to TNBC patients but chemotherapy was shown good therapeutic efficacy. However, failure in TNBCs treatment by chemotherapy is the cause of multidrug-resistant (MDR) cancer cell developed and healthy cells are disrupted, causing adverse side-effects. Therefore, identifying the molecular targets underlying chemotherapy could contribute to the development of novel cytotoxic agents as well as the improvement of TNBC killing selectivity. Cationic antimicrobial peptides (CAPs) are cytotoxic to certain cancer types, but are less toxic to normal cells. Nile Tilapia piscidin 4 (TP4) is a CAP derived from Nile tilapia (Oreochromis niloticus). Synthetic TP4 was shown to inhibit gram-positive/negative bacteria; however, its role in BC toxicity has not been investigated. In this study, three BC cell lines were used for evaluating the therapeutic efficacy of TP4 in vitro. Transcriptome study was carried out to explore the potential therapeutic factors induced by TP4 in TNBC cell. In addition, zebrafish xenograft model was developed to investigate the therapeutic efficacy of TP4 in vivo. Cell viability assay showed that synthetic TP4 selectively damages to BC cells (MDA-MB-231/MDA-MB-453/MCF-7) but is less toxic to normal cells (M10/HDF). Microarray study identified FOS family proteins were affected by TP4 treatment in TNBC cells and that overexpression of a FOS family protein, FOSB, caused dramatically TNBC cell death. In addition, we observed TNBC xenotransplantation caused significant zebrafish death in vivo; however, TP4 prolongs the survival in TNBC xenograft zebrafish under a safe dosage. In this study, we confirmed that synthetic TP4 shows selective cytotoxicity to TNBC cell and good therapeutic efficacy. We also identified FOSB as a probable prognostic factor among effective TNBC treatment. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18042 |
全文授權: | 未授權 |
顯示於系所單位: | 漁業科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.88 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。